Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia

[1]  J. Testa,et al.  Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. , 2001, Cancer letters.

[2]  O. Legrand,et al.  JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. , 2001, Blood.

[3]  A. Klein-Szanto,et al.  Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. , 2000, Journal of the National Cancer Institute.

[4]  D. Keppler,et al.  The Multidrug Resistance Protein 5 Functions as an ATP-dependent Export Pump for Cyclic Nucleotides* , 2000, The Journal of Biological Chemistry.

[5]  E. D. de Vries,et al.  P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  F. Baas,et al.  Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. van den Berg,et al.  Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity. , 2000, Blood.

[8]  T. Cantz,et al.  MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[9]  M. Wiesneth,et al.  Palliative cytoreduction in refractory acute leukemia: a retrospective study of 57 adult patients , 2000, Annals of Hematology.

[10]  R. Advani,et al.  Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). , 1999, Advances in experimental medicine and biology.

[11]  P. Sonneveld,et al.  P-gp and mrp activities in relation to treatment outcome in acute myeloid leukemia. , 1999 .

[12]  J. Schuetz,et al.  MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs , 1999, Nature Medicine.

[13]  M. Tanimoto,et al.  No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. , 1999, International journal of hematology.

[14]  M. Grever,et al.  Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. , 1999, Blood.

[15]  O. Legrand,et al.  Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. , 1999, Blood.

[16]  D. Keppler,et al.  Export pumps for anionic conjugates encoded by MRP genes. , 1999, Advances in enzyme regulation.

[17]  G. Peters,et al.  MRP3, an organic anion transporter able to transport anti-cancer drugs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Hagenbeek,et al.  Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? , 1999, Bone Marrow Transplantation.

[19]  M. Baccarani,et al.  P‐glycoprotein, lung resistance‐related protein and multidrug resistance associated protein in de novo acute non‐lymphocytic leukaemias: biological and clinical implications , 1999, British journal of haematology.

[20]  P. Jansen,et al.  ATP‐ and glutathione‐dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1 , 1999, British journal of pharmacology.

[21]  F. Appelbaum,et al.  Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. , 1998, The New England journal of medicine.

[22]  A. Hall,et al.  The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. , 1998, Blood.

[23]  E. van den Berg,et al.  Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  O. Legrand,et al.  Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. , 1998, Blood.

[25]  P. Sonneveld,et al.  Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  F. DuBru,et al.  Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. , 1998, Molecular pharmacology.

[27]  F. Appelbaum,et al.  A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). , 1998, Blood.

[28]  M. Kool,et al.  Expression of Human MRP 6 , a Homologue of the Multidrug Resistance Protein Gene MRP 1 , in Tissues and Cancer Cells 1 , 1998 .

[29]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[30]  E. Estey,et al.  Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  谷口堅.  A Human Canalicular Multispecific Organic Anion Transporter(cMOAT)Gene Is Overexpressed in Cisplatin-resistant Human Cancer Cell Lines with Decreased Drug Accumulation(ヒトCanalicular Multispecific Organic Anion Transporter(cMOAT)遺伝子は薬剤蓄積の減少したシスプラチン耐性ヒトがん細胞株で過剰発現している) , 1997 .

[32]  S. Cole,et al.  Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. , 1996, The Journal of biological chemistry.

[33]  I. Pastan,et al.  The multidrug-resistance gene in gene therapy of cancer and hematopoietic disorders , 1996, Annals of Hematology.

[34]  T. Klingebiel,et al.  Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. , 1996, Leukemia.

[35]  R. Zittoun,et al.  Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. , 1995, Leukemia.

[36]  S. Stass,et al.  Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. , 1995, Leukemia.

[37]  J. Merlin,et al.  Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. , 1995, Blood.

[38]  K. Cowan,et al.  Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. , 1995, Blood.

[39]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[40]  S. Simon,et al.  Cell biological mechanisms of multidrug resistance in tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Mehta,et al.  Quantitation of multidrug resistant MDR1 transcript in acute myeloid leukaemia by non‐isotopic quantitative cDNA‐polymerase chain reaction , 1994, British journal of haematology.

[42]  P. Sonneveld,et al.  Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. , 1993, Blood.

[43]  R. Burghardt,et al.  Concurrent analysis of intracellular glutathione content and gap junctional intercellular communication. , 1993, Cytometry.

[44]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[45]  T. Tsuruo,et al.  Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. , 1992, Blood.

[46]  S. Nimer,et al.  Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. , 1992, Blood.

[47]  M. Oken,et al.  Varying intensity of postremission therapy in acute myeloid leukemia. , 1992, Blood.

[48]  B. Sikic,et al.  Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. , 1991, Blood.

[49]  B. Sikic,et al.  Multidrug Resistance ( mdr l ) Gene Expression in Adult Acute Leukemias : Correlations With Treatment Outcome and In Vitro Drug Sensitivity , 2003 .

[50]  P. Sonneveld,et al.  Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  P. Sonneveld,et al.  Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study. , 1990, Haematology and blood transfusion.

[52]  A. de la Chapelle,et al.  Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse. , 1989, Cancer genetics and cytogenetics.

[53]  A. Ford-hutchinson,et al.  Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. , 1989, Canadian journal of physiology and pharmacology.

[54]  A. Burnett,et al.  TRANSPLANTATION OF UNPURGED AUTOLOGOUS BONE-MARROW IN ACUTE MYELOID LEUKAEMIA IN FIRST REMISSION , 1984, The Lancet.

[55]  G. Galloway,et al.  Malignant Hyper-Pyrexia and Sudden Infant Death , 1982 .

[56]  D. A. G. Galton,et al.  Classification of Acute Leukemia , 1977 .